Page last updated: 2024-08-21

pyrazines and mln 8237

pyrazines has been researched along with mln 8237 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Anderson, KC; Bandi, M; Bianchi, G; Calabrese, E; Carrasco, RD; Cirstea, D; Ecsedy, J; Görgün, G; Hideshima, T; Hu, Y; Ikeda, H; Mani, M; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Tai, YT; Zheng, M	1
Classe, JM; Ferron, G; Floquet, A; Freyer, G; Hardy-Bessard, AC; Kurtz, JE; Lécuru, F; Motte-Rouge, T; Pautier, P	1

Reviews

1 review(s) available for pyrazines and mln 8237

Article	Year
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer. Bulletin du cancer, 2021, Volume: 108, Issue:9S1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Azepines; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Isoxazoles; Maintenance Chemotherapy; Maytansine; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Pteridines; Pyrazines; Pyrimidines	2021

Article

Year

Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.

Bulletin du cancer, 2021, Volume: 108, Issue:9S1

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Azepines; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Isoxazoles; Maintenance Chemotherapy; Maytansine; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Pteridines; Pyrazines; Pyrimidines

2021

Other Studies

1 other study(ies) available for pyrazines and mln 8237

Article	Year
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood, 2010, Jun-24, Volume: 115, Issue:25 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Doxorubicin; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrimidines; Spindle Apparatus; Time Factors; Transplantation, Heterologous; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2010

Article

Year

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Blood, 2010, Jun-24, Volume: 115, Issue:25

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Doxorubicin; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrimidines; Spindle Apparatus; Time Factors; Transplantation, Heterologous; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2010